Status:
COMPLETED
A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Overweight and Obesity
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The aim of this study is to look at how the study medicine behaves in participants body and how it is removed from their body. The study compares three different doses of the study medicine in Chines...
Eligibility Criteria
Inclusion
- Key inclusion criteria
- Chinese male subject aged 18-55 years (both inclusive) at the time of signing informed consent.
- Body mass index (BMI) between 20.0 and 39.9 kg/m\^2 (both inclusive) at screening.
- Body weight between 60.0 and 110.0 kg (both inclusive) at screening.
- Key exclusion criteria
- Male subject who is not sexually abstinent or surgically sterilised (vasectomy) or who or whose partner(s) is not willing to use highly effective contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial').
- Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Exclusion
Key Trial Info
Start Date :
March 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 7 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05254158
Start Date
March 3 2022
End Date
September 7 2022
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China, 200031